Helix BioMedix

HXBM · OTC

$3.29+$3.71 (−883.33%)TodayMarket closed · Oct 13, 10:57 AM ET

No price history for this range.

About HXBM

Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is in the preclinical stage of development and intends to file for orphan drug designation prior to entering the clinical development pathway. Its legacy business consists of an proprietary library of patented bioactive peptides. Its lead drug development candidate, HB4208, is a polypeptide DNA deoxyribonucleic (DNA) damage response (DDR) enzyme for topical treatment of the rare genetic disorder (orphan disease) XP. Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. The company is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. The company is also engaged in the treatment of skin conditions.

Employees: 8
Headquarters: Bothell, Washington
Listed: Jul 25, 2000
Sector: Health Care
Industry: Biotechnology
Website: helixbiomedix.com

Leadership

Helix BioMedix executives
Name	Title	Since	Age
R. Stephen Beatty	—	1999	73
Robin Carmichael	—	2007	66
John Clifford	—	—	80
Richard Cohen	—	—	72
William Goolsbee	—	—	69
Lawrence Jones	—	—	76

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Helix BioMedix suppliers and customers
Company	Relationship	Country	Correlation
Polaris Group	Supplier	TW	—

Similar companies

Companies in the same industry as Helix BioMedix

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.